폐경기 증상을 완화시키기 위한 개별화 호르몬 요법에 대한 고찰: 다른 위험요소가 없는 폐경기 여성을 중심으로
Hormone Therapy Review for Perimenopausal Symptoms: Focused on Perimenopausal Women without Other Risk Factors
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
As the population ages, the life of women after menopause becomes much longer than the past, and the quality of life of old agebecomes increasingly principal issue. There is a period that women experience the physical symptoms of menopause, althoughthere are differences in degree, and the management of this period is a suitable time for women to improve their quality of life. According to the menopausal hormone therapy (MHT) and Timing Hypothesis, which has been proven in the Kronos Early EstrogenPrevention Study (KEEPS) and the Early vs Late Intervention Trial with Estradiol (ELITE) study, a relatively young woman before andafter menopause can benefit from long-term beneficial effects such as prevention of osteoporosis and cardiovascular disease byearly initiation of hormone therapy to alleviate menopausal symptoms. MHT should be considered for all women in healthy (withoutother important diseases) menopausal years, expecting to improve their quality of life through symptom relief in menopausal womenand, in the long term, to prevent cardiovascular disease and osteoporosis. When applying hormone therapy to individuals, it isnecessary to establish various treatment strategies according to the menopausal symptoms of individual patients (individualizationof treatment) and judge the suitability of clinical application.
Abstract
As the population ages, the life of women after menopause becomes much longer than the past, and the quality of life of old agebecomes increasingly principal issue. There is a period that women experience the physical symptoms of menopause, althoughthere are differences in degree, and the management of this period is a suitable time for women to improve their quality of life. According to the menopausal hormone therapy (MHT) and Timing Hypothesis, which has been proven in the Kronos Early EstrogenPrevention Study (KEEPS) and the Early vs Late Intervention Trial with Estradiol (ELITE) study, a relatively young woman before andafter menopause can benefit from long-term beneficial effects such as prevention of osteoporosis and cardiovascular disease byearly initiation of hormone therapy to alleviate menopausal symptoms. MHT should be considered for all women in healthy (withoutother important diseases) menopausal years, expecting to improve their quality of life through symptom relief in menopausal womenand, in the long term, to prevent cardiovascular disease and osteoporosis. When applying hormone therapy to individuals, it isnecessary to establish various treatment strategies according to the menopausal symptoms of individual patients (individualizationof treatment) and judge the suitability of clinical application.
참고문헌 (35)
- Kuhl H, "Pharmacology of estrogens and progestogens: influence of different routes of administration", Climacteric, 8(suppl 1), pp.3~63 (2005)
- Yoon BK., "Development of the protocol to evaluate the effects of hormone therapy in postmenopausal women", The 3rd Symposium on Women's Health Research (2014)
- 조문경, "국내 폐경 호르몬 약제의 2010년 사용 현황", 대한폐경학회지, 17(3), pp.150~154 (2011), 대한폐경학회
- 한기옥, "호르몬 치료에 대한 최신지견", Endocrinology and Metabolism, 22(5), pp.317~322 (2007), 대한내분비학회
- Park HM, "Female hormone therapy tendency after WHI. The Korean Clinical Elderly Medical Society", Fall Conference 2006 (2006)
- Miller VM, "Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification : Kronos Early Estrogen Prevention Study", Physiol Genomics, 48(1), pp.33~41 (2016)
- Hodis HN, "Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol", N Engl J Med, 374(13), pp.1221~1231 (2016)
- Gallagher JC, "Effect of conjugated estrogens", bazedoxifene on postmenopausal bone loss : pooled analysis of two randomized trials, 2016, pp.23(10), 1083~1091
- Cintron D, "Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)", Menopause (2017)
- Harman SM, "KEEPS : The Kronos Early Estrogen Prevention Study", Climacteric, 8(1), pp.3~12 (2005)
- Kling JM, "Endothelial function in women of the Kronos Early Estrogen Prevention Study", Climacteric, 18(2), pp.187~197 (2015)
- Santoro N, "Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo : the Kronos Early Estrogen Prevention Study", Menopause, 24(3), pp.238~246 (2017)
- Gleason CE, "Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women:Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study", PLoS Med, 12(6), pp.e1001833~ (2015)
- Manson JE, "Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials", JAMA, 310(13), pp.1353~1368 (2013)
- Lindsay R, "Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women", Osteoporos Int, 16(4), pp.372~379 (2005)
- Gambacciani M, "Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women", Maturitas, 59(1), pp.2~6 (2008)
- Sturdee DW, "Ultra-low-dose continuous combined estradiol and norethisterone acetate : improved bleeding profile in postmenopausal women", Climacteric, 11(1), pp.63~73 (2008)
- De Franciscis P, "Low-dose hormone therapy in the perimenopause", Int J Gynaecol Obstet, 98(2), pp.138~142 (2007)
- Sturdee DW, "Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health", Climacteric, 14, pp.302~320 (2011)
- Bodmer C, "Hormonersatztherapie (HET)- Guidelines fur die Schweiz", Gynakol Endokrinol, 3, pp.26~30 (2009)
- Coelingh Bennink HJ., "Are all estrogens the same?", Maturitas, 47(4), pp.269~275 (2004)
- Cummings JA, "Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women", Menopause, 9(4), pp.253~263 (2002)
- Fournier A, "Unequal risks for breast cancer associated with different hormone replacement therapies : results from the E3N cohort study", Breast Cancer Res Treatment, 107, pp.103~111 (2008)
- Olie V, "Hormone therapy and recurrence of venous thromboembolism among postmenopausal women", Menopause, 18, pp.488~493 (2011)
- Canonico M, "Hormone therapy and venous thromboembolism among postmenopausal women : impact of the route of estrogen administration and progestogens : the ESTHER study", Circulation, 115, pp.840~845 (2007)
- Schierbeck LL, "Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial", BMJ, 345, pp.e6409~ (2012)
- Grodstein F, "Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation", Women’s Health, 15, pp.35~44 (2006)
- Stute P, "Ultra-low dose-new approaches in menopausal hormone therapy", Climacteric, 18(2), pp.182~186 (2015)
- North American Menopause Society, "The 2012 hormone therapy position statement of : The North American Menopause Society", Menopause, 19, pp.257~271 (2012)
- Marjoribanks J, "Cochrane corner: longterm hormone therapy for perimenopausal and postmenopausal women", Heart (2017)
- Cobin RH, "American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause-2017 update", Endocr Pract, 23(7), pp.869~880 (2017)
- Manassiev N, "Effects of tibolone or continuous combined oestradiol", norethisterone acetate on glucose and insulin metabolism, 2013, pp.78, 297~302
- Inan I, "Psychological effects of tibolone and sequential estrogen-progestogen therapy in perimenopausal women", Gynecol Endocrinol, 20(2), pp.64~67 (2005)
- Formoso G, "Short-term and long-term effects of tibolone in postmenopausal women", Cochrane Database Syst Rev, 10, pp.CD008536~ (2016)